LINDELL ANDREA R sold $603K of CHE

LINDELL ANDREA R sold 1,347 shares of CHEMED CORP (CHE) at $447.33 ($0.60M total) on 2026-06-09.

Original reporting
SEC EDGAR · LINDELL ANDREA R
Published Jun 10, 2026, 5:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 5:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CHE
Neutral
medium confidence
Mentioned
$CHE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CHENeutralLow
01

Why it matters

A director’s open-market sale provides incremental sentiment information but does not, by itself, change CHE’s operating outlook.

02

Market read

Traders may note insider selling as a mild negative sentiment datapoint, but there is no new fundamental catalyst in the text.

03

What to watch

Because the article is only a Form 4, it lacks context on total insider activity, prior sales, and whether other insiders/owners are buying or selling around the same period.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-10; sale executed 2026-06-09

Background

The article is an SEC Form 4 insider transaction disclosure for Chemed Corp (CHE).

Company-level read

Ticker impact

$CHENeutralMedium confidence
Context

Director Lin(dell) Andrea R filed an open-market sale of 1,347 CHE shares for about $602.6K on 2026-06-09.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than a fundamental catalyst.

Evidence & confidence

Form 4 insider sales can be informational, but this is a single director sale with no accompanying company-specific news (earnings, guidance, deals, or enforcement).

Market effects

No sector-level read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The sale may be unrelated to fundamentals (tax/portfolio rebalancing), especially since the filing does not indicate a planned 10b5-1 structure.

Key entities

  • CHEMED CORP

    Issuer of the insider transaction disclosed on SEC Form 4.

  • LINDELL ANDREA R

    Director who sold 1,347 shares of CHE for ~$602.6K.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.

$CHEHighAI 8/10

Why is Chemed stock surging today?

Chemed (CHE) stock rose 9.2% after Q3 earnings beat estimates, with adjusted EPS of $6.75 and revenue of $690.9M. VITAS hospice division showed strong growth. Jefferies upgraded the stock to Buy, raising its price target to $620. Bank of America also increased its target to $555. The stock hit a 52-week high.